MariTide
GLP-1 + GIPR antagonist (antibody) · s.c. monthly · Amgen
Summary
- Also known as
- maridebart cafraglutide
- Mechanism
- GLP-1 + GIPR antagonist (antibody)
- Route
- s.c. monthly
- Company
- Amgen
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 (MARITIME) verify
- Next milestone
- MARITIME-1/-2 readouts 2027
Sources for the status
- Amgen. A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. ClinicalTrials.gov identifier NCT05669599. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05669599
- Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. PMID: 40549887.
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | MARITIME phase 3 programme ongoing | |
| T2D | 2 phase 3 ongoing | Phase 3 ongoing | |
| CV outcomes | 2 phase 3 ongoing | Phase 3 ongoing | |
| CKD | 0 no data | ||
| HFpEF | 2 phase 3 ongoing | Phase 3 ongoing | |
| MASH | 0 no data | ||
| Sleep apnoea | 2 phase 3 ongoing | Phase 3 ongoing | |
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MariTide phase 2 (obesity cohort) | MariTide 140 mg every 4 weeks (no escalation) | obesity | 52 | 77 | −16.3 % vs −2.6 % Δ −13.7 pp | −13.6 % vs −2.5 % Δ −11.1 pp | — | 14.0 vs 1.0 | — | 77.0 vs 25.0 | 68.0 vs 3.0 | 5.0 vs 7.0 | — | verified |
| MariTide phase 2 (obesity cohort) | MariTide 280 mg every 4 weeks (no escalation) | obesity | 52 | 77 | −19.9 % vs −2.6 % Δ −17.3 pp | −15.5 % vs −2.5 % Δ −13.0 pp | — | 14.0 vs 1.0 | — | 78.0 vs 25.0 | 73.0 vs 3.0 | 5.0 vs 7.0 | — | verified |
| MariTide phase 2 (obesity cohort) | MariTide 420 mg every 4 weeks (no escalation) | obesity | 52 | 79 | −18.9 % vs −2.6 % Δ −16.3 pp | −14.6 % vs −2.5 % Δ −12.1 pp | — | 22.0 vs 1.0 | — | 87.0 vs 25.0 | 87.0 vs 3.0 | 6.0 vs 7.0 | — | verified |
| MariTide phase 2 (obesity cohort) | MariTide 420 mg every 8 weeks (no escalation) | obesity | 52 | 51 | −17.7 % vs −2.6 % Δ −15.1 pp | −12.3 % vs −2.5 % Δ −9.8 pp | — | 29.0 vs 1.0 | — | 82.0 vs 25.0 | 92.0 vs 3.0 | 14.0 vs 7.0 | — | verified |
| MariTide phase 2 (obesity cohort) | MariTide 420 mg every 4 weeks, 4-week dose escalation | obesity | 52 | 51 | −16.7 % vs −2.6 % Δ −14.1 pp | −14.1 % vs −2.5 % Δ −11.6 pp | — | 10.0 vs 1.0 | — | 71.0 vs 25.0 | 43.0 vs 3.0 | 0.0 vs 7.0 | — | verified |
| MariTide phase 2 (obesity cohort) | MariTide 420 mg every 4 weeks, 12-week dose escalation | obesity | 52 | 52 | −19.9 % vs −2.6 % Δ −17.3 pp | −16.2 % vs −2.5 % Δ −13.7 pp | — | 12.0 vs 1.0 | — | 73.0 vs 25.0 | 44.0 vs 3.0 | 6.0 vs 7.0 | — | verified |
| MariTide phase 2 (obesity with T2D cohort) | MariTide 140 mg every 4 weeks (no escalation) | t2d | 52 | 31 | −12.3 % vs −1.4 % Δ −10.9 pp | −10.3 % vs −1.7 % Δ −8.6 pp | −1.6 vs +0.1 | 13.0 vs 3.0 | — | 58.0 vs 9.0 | 45.0 vs 6.0 | 3.0 vs 0.0 | — | verified |
| MariTide phase 2 (obesity with T2D cohort) | MariTide 280 mg every 4 weeks (no escalation) | t2d | 52 | 32 | −12.1 % vs −1.4 % Δ −10.7 pp | −8.4 % vs −1.7 % Δ −6.7 pp | −1.2 vs +0.1 | 19.0 vs 3.0 | — | 41.0 vs 9.0 | 50.0 vs 6.0 | 6.0 vs 0.0 | — | verified |
| MariTide phase 2 (obesity with T2D cohort) | MariTide 420 mg every 4 weeks (no escalation) | t2d | 52 | 32 | −17.0 % vs −1.4 % Δ −15.6 pp | −12.3 % vs −1.7 % Δ −10.6 pp | −1.5 vs +0.1 | 16.0 vs 3.0 | — | 59.0 vs 9.0 | 75.0 vs 6.0 | 12.0 vs 0.0 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- MariTide 140 mg every 4 weeks (no escalation): Obesity cohort. Nausea and vomiting may include reports from a solicited questionnaire to week 12 (authors note possible ascertainment bias; placebo nausea 25 %). Any discontinuation is only given as a range across arms (supplementary figure); SBP in the supplement only.
- MariTide 280 mg every 4 weeks (no escalation): Obesity cohort. Nausea and vomiting may include reports from a solicited questionnaire to week 12 (authors note possible ascertainment bias; placebo nausea 25 %). Any discontinuation is only given as a range across arms (supplementary figure); SBP in the supplement only.
- MariTide 420 mg every 4 weeks (no escalation): Obesity cohort. Nausea and vomiting may include reports from a solicited questionnaire to week 12 (authors note possible ascertainment bias; placebo nausea 25 %). Any discontinuation is only given as a range across arms (supplementary figure); SBP in the supplement only.
- MariTide 420 mg every 8 weeks (no escalation): Obesity cohort. Nausea and vomiting may include reports from a solicited questionnaire to week 12 (authors note possible ascertainment bias; placebo nausea 25 %). Any discontinuation is only given as a range across arms (supplementary figure); SBP in the supplement only.
- MariTide 420 mg every 4 weeks, 4-week dose escalation: Obesity cohort. Nausea and vomiting may include reports from a solicited questionnaire to week 12 (authors note possible ascertainment bias; placebo nausea 25 %). Any discontinuation is only given as a range across arms (supplementary figure); SBP in the supplement only.
- MariTide 420 mg every 4 weeks, 12-week dose escalation: Obesity cohort. Nausea and vomiting may include reports from a solicited questionnaire to week 12 (authors note possible ascertainment bias; placebo nausea 25 %). Any discontinuation is only given as a range across arms (supplementary figure); SBP in the supplement only.
- MariTide 140 mg every 4 weeks (no escalation): Obesity with type 2 diabetes cohort (1:1:1:1, no dose escalation). Any discontinuation is only given as a range across arms (supplementary figure); SBP in the supplement only.
- MariTide 280 mg every 4 weeks (no escalation): Obesity with type 2 diabetes cohort (1:1:1:1, no dose escalation). Any discontinuation is only given as a range across arms (supplementary figure); SBP in the supplement only.
- MariTide 420 mg every 4 weeks (no escalation): Obesity with type 2 diabetes cohort (1:1:1:1, no dose escalation). Any discontinuation is only given as a range across arms (supplementary figure); SBP in the supplement only.
Verbatim quotes from the source (57)
- MariTide 140 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
- MariTide 140 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 1 of 1
Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
- MariTide 140 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
- MariTide 140 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 1
Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
- MariTide 140 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
- MariTide 140 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
- MariTide 280 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
- MariTide 280 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 2 of 1
Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
- MariTide 280 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
- MariTide 280 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 2
Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
- MariTide 280 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
- MariTide 280 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
- MariTide 420 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
- MariTide 420 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 3 of 1
Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
- MariTide 420 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
- MariTide 420 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 3
Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
- MariTide 420 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
- MariTide 420 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
- MariTide 420 mg every 8 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
- MariTide 420 mg every 8 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 4 of 1
Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
- MariTide 420 mg every 8 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
- MariTide 420 mg every 8 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 4
Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
- MariTide 420 mg every 8 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
- MariTide 420 mg every 8 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
- MariTide 420 mg every 4 weeks, 4-week dose escalation · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
- MariTide 420 mg every 4 weeks, 4-week dose escalation · weight_eff · Table 2, Efficacy estimand, Primary end point; column 5 of 1
Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
- MariTide 420 mg every 4 weeks, 4-week dose escalation · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
- MariTide 420 mg every 4 weeks, 4-week dose escalation · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 5
Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
- MariTide 420 mg every 4 weeks, 4-week dose escalation · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
- MariTide 420 mg every 4 weeks, 4-week dose escalation · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
- MariTide 420 mg every 4 weeks, 12-week dose escalation · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
- MariTide 420 mg every 4 weeks, 12-week dose escalation · weight_eff · Table 2, Efficacy estimand, Primary end point; column 6 of 1
Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
- MariTide 420 mg every 4 weeks, 12-week dose escalation · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
- MariTide 420 mg every 4 weeks, 12-week dose escalation · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 6
Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
- MariTide 420 mg every 4 weeks, 12-week dose escalation · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
- MariTide 420 mg every 4 weeks, 12-week dose escalation · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
- MariTide 140 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
- MariTide 140 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 8 of 1
Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
- MariTide 140 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
- MariTide 140 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 8
Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
- MariTide 140 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
- MariTide 140 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
- MariTide 140 mg every 4 weeks (no escalation) · hba1c · Table 2, Treatment policy estimand, Key secondary; column 8
Change in glycated hemo- globin — percentage points −0.3 (−0.4 to −0.3) −0.4 (−0.5 to −0.3) −0.3 (−0.3 to −0.2) −0.3 (−0.4 to −0.2) −0.3 (−0.4 to −0.3) −0.3 (−0.4 to −0.3) 0.0 (−0.1 to 0.1) −1.6 (−1.9 to −1.2) −1.2 (−1.7
- MariTide 280 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
- MariTide 280 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 9 of 1
Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
- MariTide 280 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
- MariTide 280 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 9
Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
- MariTide 280 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
- MariTide 280 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
- MariTide 280 mg every 4 weeks (no escalation) · hba1c · Table 2, Treatment policy estimand, Key secondary; column 9
Change in glycated hemo- globin — percentage points −0.3 (−0.4 to −0.3) −0.4 (−0.5 to −0.3) −0.3 (−0.3 to −0.2) −0.3 (−0.4 to −0.2) −0.3 (−0.4 to −0.3) −0.3 (−0.4 to −0.3) 0.0 (−0.1 to 0.1) −1.6 (−1.9 to −1.2) −1.2 (−1.7
- MariTide 420 mg every 4 weeks (no escalation) · weight_tp · Table 2, Treatment policy estimand, Primary end point; colum
Mean percent change in body weight −13.6 (−15.5 to −11.7) −15.5 (−17.7 to −13.4) −14.6 (−16.8 to −12.4) −12.3 (−15.0 to −9.7) −14.1 (−16.2 to −12.1) −16.2 (−18.9 to −13.5) −2.5 (−4.2 to −0.7) −10.3 (−13.2 to −7.4) −8.4 (
- MariTide 420 mg every 4 weeks (no escalation) · weight_eff · Table 2, Efficacy estimand, Primary end point; column 10 of
Mean percent change in body weight −16.3 (−17.5 to −15.2) −19.9 (−21.1 to −18.6) −18.9 (−20.2 to −17.6) −17.7 (−19.3 to −16.1) −16.7 (−18.0 to −15.4) −19.9 (−21.4 to −18.4) −2.6 (−3.6 to −1.5) −12.3 (−14.1 to −10.4) −12.
- MariTide 420 mg every 4 weeks (no escalation) · ae_dc · Table 3 (Safety and Adverse Events), row "Adverse events lea
Adverse events leading to discontinuation of trial regimen 11 (14) 11 (14) 17 (22) 15 (29) 5 (10) 6 (12) 1 (1) 4 (13) 6 (19) 5 (16) 1 (3)
- MariTide 420 mg every 4 weeks (no escalation) · nausea · Table 3 (Safety and Adverse Events), row "Nausea", column 10
Nausea 59 (77) 60 (78) 69 (87) 42 (82) 36 (71) 38 (73) 19 (25) 18 (58) 13 (41) 19 (59) 3 (9)
- MariTide 420 mg every 4 weeks (no escalation) · vomiting · Table 3 (Safety and Adverse Events), row "Vomiting", column
Vomiting 52 (68) 56 (73) 69 (87) 47 (92) 22 (43) 23 (44) 2 (3) 14 (45) 16 (50) 24 (75) 2 (6)
- MariTide 420 mg every 4 weeks (no escalation) · sae · Table 3 (Safety and Adverse Events), row "Serious adverse ev
Serious adverse event 4 (5) 4 (5) 5 (6) 7 (14) 0 3 (6) 5 (7) 1 (3) 2 (6) 4 (12) 0
- MariTide 420 mg every 4 weeks (no escalation) · hba1c · Table 2, Treatment policy estimand, Key secondary; column 10
Change in glycated hemo- globin — percentage points −0.3 (−0.4 to −0.3) −0.4 (−0.5 to −0.3) −0.3 (−0.3 to −0.2) −0.3 (−0.4 to −0.2) −0.3 (−0.4 to −0.3) −0.3 (−0.4 to −0.3) 0.0 (−0.1 to 0.1) −1.6 (−1.9 to −1.2) −1.2 (−1.7
Outcome trials
Ongoing outcome trials
| Trial | Molecule | Population | Primary endpoint | n | Registry status | Primary completion | Registry |
|---|---|---|---|---|---|---|---|
| MARITIME-CV | MariTide | Obesity with established CVD Obesity + established CVD, with or without T2D | MACE | 12800 | recruiting | 2028-06-30 | NCT07037433 |
Registered trials (12)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| MARITIME-T2D-3 Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | T2D | Phase 3 | recruiting | 2026-10 → 2028-09 | 1300 | recruiting | NCT07866066 |
| MARITIME-PEN Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Obesity | Phase 3 | recruiting | 2026-10 → 2027-06 | 230 | recruiting | NCT07871409 |
| MARITIME-2-EXTENSION Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | T2D | Phase 3 | recruiting | 2026-07 → 2027-12 | 950 | recruiting | NCT07684144 |
| MARITIME-1-EXTENSION Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) | Obesity | Phase 3 | recruiting | 2026-07 → 2027-12 | 3200 | recruiting | NCT07684235 |
| MARITIME-SWITCH Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) | Obesity | Phase 3 | recruiting | 2026-05 → 2028-01 | 300 | recruiting | NCT07575399 |
| MARITIME-OSA-1 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | Sleep apnoea | Phase 3 | active not recruiting | 2025-12 → 2027-08 | 250 | active not recruiting | NCT07225686 |
| MARITIME-OSA-2 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | Sleep apnoea | Phase 3 | active not recruiting | 2025-11 → 2027-08 | 250 | active not recruiting | NCT07226765 |
| MARITIME-CV Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | CV outcomes | Phase 3 | active not recruiting | 2025-07 → 2028-06 | 12800 | NCT07037433 | |
| MARITIME-3-J Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease | Obesity | Phase 3 | active not recruiting | 2025-06 → 2027-04 | 279 | active not recruiting | NCT06987695 |
| MARITIME-HF Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | HFpEF | Phase 3 | recruiting | 2025-06 → 2028-06 | 5056 | recruiting | NCT07037459 |
| MARITIME-1 Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Obesity | Phase 3 | active not recruiting | 2025-03 → 2027-01 | 3853 | active not recruiting | NCT06858839 |
| MARITIME-2 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Obesity | Phase 3 | active not recruiting | 2025-03 → 2027-01 | 1105 | active not recruiting | NCT06858878 |
Primary sources
- Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. PMID: 40549887.
- Amgen. A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. ClinicalTrials.gov identifier NCT05669599. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05669599
- Amgen. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV). ClinicalTrials.gov identifier NCT07037433. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07037433
How to cite this page
Cite the primary publication for any single result; every value above links to it.